Dr. Raymond L. Comenzo, MD

Dr. Comenzo practices at Tufts Medical Center in Boston, Massachusetts, part of Tufts Medicine.

Dr. Comenzo's NPI, 1750352787, was assigned on January 28, 2006. Dr. Comenzo graduated from Boston University School Of Medicine in 1986. Dr. Comenzo's New York license number on file is 212755.

Dr. Comenzo's primary practice is Tufts Medical Center, at 800 Washington Street, Boston, MA 02111 in Suffolk County. The practice phone is (617) 636-5000.

Dr. Comenzo's primary practice is Tufts Medical Center in Boston, Massachusetts, part of Tufts Medicine. Dr. Comenzo is also affiliated with Lowell General Hospital. The medical group on file is Pratt Medical Group, Inc. - General Medical Associates (General Internal Medicine). Dmand AI also links Dr. Comenzo to 1 more imaging center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Comenzo practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Comenzo's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Comenzo is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Comenzo's licenses on file in 2 states: New York and Massachusetts.

Dmand AI lists chronic leukemia, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Comenzo treats.

CMS data shows 314 Medicare services from Dr. Comenzo across 4 procedure codes in 2024, for 95 Medicare patients. Medicare paid $23,318 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 95 Medicare patients who saw Dr. Comenzo in 2024. The largest group is 65 to 74, with 44 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 3.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Comenzo's median patient age at 68, with 50% women.

In 2024, Dr. Comenzo wrote 21 Medicare Part D claims. 95% of them were for generic drugs. They cover 3 drugs, with $510 in total drug cost. In 2018, CMS named 46 claims across 2 drugs.

Dr. Comenzo accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 178 papers to Dr. Comenzo, published from 2003 to 2025. 2020 was the busiest year, with 15. The most frequent topics are Amyloidosis, Multiple Myeloma and Hematopoietic Stem Cell Transplantation. Dr. Comenzo has published most often in Blood. Dr. Comenzo's most frequent co-authors are Cindy Iris Varga, MD, Hani Hassoun, MD and Stephen D. Nimer, MD.

Dmand AI links Dr. Comenzo to 18 clinical trials, 6 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Amyloidosis, Immunoglobulin Light-chain Amyloidosis and Multiple Myeloma. Prothena Biosciences Ltd. sponsors the most, 4. Open Payments lists research payments to Dr. Comenzo that name 1 trial.

CMS Open Payments shows 51 general payments to Dr. Comenzo from 9 drug and device companies from 2016 to 2023. Consulting fees make up the largest share, 97% of the total. Janssen Research & Development, LLC paid the most, $37,590. It also lists 2 research payments totaling $163 from 2016 to 2019, naming 1 clinical trial.

Dmand AI lists 4 awards for Dr. Comenzo, most recently America's Top Doctors in 2014.

Dr. Comenzo graduated from Boston University School Of Medicine in 1986.

Dr. Comenzo is in network with 17 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.